42
Views
32
CrossRef citations to date
0
Altmetric
Original Article

Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures

, , , , &
Pages 230-237 | Published online: 05 Aug 2009

References

  • Riis B J, Rodbro O, Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int 1986; 38: 318–22
  • Steimicke T, Hasling C, Charles P, et al. A randomised study on the effects of oestrogen–gestagen or high dose oral calcium on trabecular oral calcium on trabecular bone remodelling in postmenopausal osteoporosis. Bone 1989; 10: 313–20
  • Ferguson K J, Hoegh C, Johnson S. Oestrogen replacement therapy. A survey of women's knowledge and attitudes. Arch Int Med 1989; 149: 133–6
  • Hahn R G. Compliance considerations with oestrogen replacement: withdrawal bleeding and other factors. Am J Obst Gyn 1989; 161: 1854–8
  • Felson D T, Zhang Y, Hannan M T, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–6
  • de Visser J, Coert A, Feenstra H, et al. Endocrinological studies with (7α, 17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD14). Arzneimittelforsch/Drug Res 1984; 34: 1010–17
  • Kicovic P M, Cortes-Prieto J, Luisi M, et al. Placebo controlled cross-over study of effects of Org OD14 in menopausal women. Reproduction 1982; 6: 81–91
  • Nevinny-Stickel J. Double-blind cross-over study with Org OD14 and placebo in postmenopausal patients. Arch Gynecol 1983; 234: 27–31
  • Benedek-Jaszmann L J. Long-term placebo-controlled efficacy and safety study of Org OD14 in climacteric women. Maturitas 1987; 1: 25–33, Suppl
  • Punnonen R, Liukko P, Cortes-Prieto J, et al. Multicentre study of effects of Org OD14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas 1984; 5: 281–6
  • Genazzani A R, Benedek-Jaszmann L J, Hart D M, et al. Org OD14 and the endometrium. Maturitas 1991; 13: 243–51
  • Lindsay R, Hart D M, Kraszewski A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. Br Med J 1980; 280: 1207–9
  • Fogelman I, Bessent R G, Smith M L, et al. Assessment of synthetic steroid (Org OD14): effect on skeletal metabolism by 24-h whole-body retention of diphosphonate. Maturitas 1981; 3: 265–9
  • Rymer J, Chapman M G, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314–19
  • Bjarnason N, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2419–22
  • Berning B, van Kuijk C, Kuiper J W, et al. The effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two year randomized placebo controlled study. Bone 1996; 19: 395–9
  • Thiebaud D, Bigler J M, Renteria S, et al. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric 1998; 1: 202–10
  • Geusens P, Dequeker J, Gielen J, et al. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991; 13: 155–62
  • Studd J, Armala I, Kicovic P M, et al. A randomized study of tibolone on bone mineral density in osteoporostic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92: 574–9
  • Lindsay C P, Shaw R W, Coelingh Bennink HJT, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996; 6592: 342–8
  • WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 1994, WHO Technical Report 843
  • Genant K G, Wu C Y, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Min Res 1993; 8: 1137–48
  • Roux C, Fechtenbaum I. Preliminary report on the evaluation of X-rays from patients treated with Org OD14 or placebo for 2 years. 1996, NV Organon, on file
  • Barentsen R, Foekema H A, Bezemer W, et al. The view of women aged 45–65 and their partners on aspects of climacteric phase of life. Eur J Obstet Gynecol Reprod Biol 1994; 57: 95–101
  • Compston J E, Yamaguchi K, Croucher P I, et al. The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995; 16(2)261–7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.